Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products

You may also be interested in...



Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22

Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22

Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

Boehringer Ingelheim's Pradaxa has set the bar by showing superiority to standard-of-care warfarin, and Daiichi Sankyo has staked a lot on an ongoing Phase III comparison study of Lixiana (edoxaban) to warfarin for the prevention of thromboembolism in atrial fibrillation, expected to report in 2012.

Related Content

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel